ABCL
AbCellera Biologics Inc.
Price Chart
Latest Quote
$5.62
-0.75 (-11.77%)
Current Price
| Previous Close | $6.37 |
| Open | $6.20 |
| Day High | $6.33 |
| Day Low | $5.50 |
| Volume | 8,896,875 |
Stock Information
| Shares Outstanding | 305.38M |
| Total Debt | $134.31M |
| Cash Equivalents | $504.73M |
| Revenue | $79.21M |
| Net Income | $-143.96M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.72B |
| EPS (TTM) | $-0.48 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.57B |
| Sales | $79.21M |
| Income | $-143.96M |
| Book/sh | $3.09 |
| Cash/sh | $1.65 |
| Employees | 562 |
Financial Ratios
| Quick Ratio | 11.45 |
| Current Ratio | 14.05 |
| Debt/Eq | 14.32 |
Returns & Margins
| ROA | -9.99% |
| ROE | -14.68% |
| Gross Margin | -135.87% |
| Operating Margin | -691.75% |
| Profit Margin | -181.74% |
Ownership
| Insider Ownership | 22.79% |
| Institutional Ownership | 43.15% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -7.81 |
| P/S | 21.67 |
| P/B | 1.82 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $10.43 |
Technical Indicators
| SMA20 | $5.24 |
| SMA50 | $4.43 |
| SMA200 | $4.21 |
| RSI | 66.17 |
| ATR | 0.5786 |
| Shares Float | 205.32M |
| Short Float | 18.23% |
| Short Ratio | 4.98 |
| Rel Volume | 0.96 |
Performance History
| Week | -8.91% |
| Month | +11.51% |
| Quarter | +62.90% |
| 6 Months | +61.03% |
| YTD | +63.85% |
| Year | +132.23% |
| 3 Years | -19.37% |
| 5 Years | -79.05% |
| 10 Years | -90.46% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $5.62 | 8,896,875 |
| 2026-06-04 | $6.37 | 11,445,900 |
| 2026-06-03 | $5.72 | 7,077,600 |
| 2026-06-02 | $6.13 | 8,065,300 |
| 2026-06-01 | $6.46 | 9,678,400 |
| 2026-05-29 | $6.17 | 9,333,400 |
| 2026-05-28 | $5.73 | 7,675,400 |
| 2026-05-27 | $5.44 | 6,471,800 |
| 2026-05-26 | $5.29 | 8,717,600 |
| 2026-05-22 | $5.20 | 6,466,600 |
| 2026-05-21 | $5.14 | 13,962,700 |
| 2026-05-20 | $4.57 | 8,513,100 |
| 2026-05-19 | $4.05 | 4,600,600 |
| 2026-05-18 | $4.16 | 11,105,000 |
| 2026-05-15 | $4.09 | 8,869,900 |
| 2026-05-14 | $4.40 | 7,372,200 |
| 2026-05-13 | $4.77 | 5,954,500 |
| 2026-05-12 | $4.95 | 16,942,400 |
| 2026-05-11 | $5.25 | 13,448,700 |
| 2026-05-08 | $5.24 | 10,843,200 |
| 2026-05-07 | $4.82 | 11,639,900 |
| 2026-05-06 | $5.04 | 7,702,500 |
About AbCellera Biologics Inc.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
đ° Latest News
AbCellera Biologics Bets on Hot Flash Antibody as Pipeline Pivot Gains Steam
MarketBeat âĸ 2026-06-04T17:02:22Z
Has ABCELLERA BIOLG (ABCL) Outpaced Other Medical Stocks This Year?
Zacks âĸ 2026-06-01T13:40:03Z
After Golden Cross, AbCellera Biologics Inc. (ABCL)'s Technical Outlook is Bright
Zacks âĸ 2026-05-29T13:55:02Z
Does AbCellera (ABCL) Have a Clear Path From ABCL635 Data to a Durable Business Model?
Simply Wall St. âĸ 2026-05-24T14:13:22Z
Hereâs Why AbCellera (ABCL) is Among the 10 Best Penny Stocks to Buy for Long Term
Insider Monkey âĸ 2026-05-22T18:43:39Z
Wall Street Analysts Believe ABCELLERA BIOLG (ABCL) Could Rally 97.28%: Here's is How to Trade
Zacks âĸ 2026-05-22T13:55:02Z
7 Healthcare AI Stocks Under $50 With Huge Upside Potential
24/7 Wall St. âĸ 2026-05-18T11:35:19Z
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?
Zacks âĸ 2026-05-14T13:40:03Z
Earnings Update: Here's Why Analysts Just Lifted Their AbCellera Biologics Inc. (NASDAQ:ABCL) Price Target To US$10.14
Simply Wall St. âĸ 2026-05-14T12:58:53Z
AbCellera Moves ABCL635 Into Phase 2 As Losses Continue
Simply Wall St. âĸ 2026-05-13T00:27:41Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $75,128,000 | $28,833,000 | $38,025,000 | $485,424,000 |
| Operating Revenue | $75,128,000 | $28,833,000 | $38,025,000 | $485,424,000 |
| Reconciled Cost Of Revenue | - | $0 | $0 | $61,177,000 |
| Cost Of Revenue | - | $0 | $0 | $66,436,000 |
| Expenses | ||||
| Total Expenses | $278,341,000 | $329,979,000 | $261,077,000 | $258,359,000 |
| Other Income Expense | $-2,711,000 | $62,278,000 | $6,776,000 | $-4,045,000 |
| Other Non Operating Income Expenses | $-2,711,000 | $62,278,000 | $6,776,000 | $-4,045,000 |
| Net Non Operating Interest Income Expense | $28,329,000 | $38,473,000 | $42,247,000 | $16,079,000 |
| Operating Expense | $278,341,000 | $329,979,000 | $261,077,000 | $191,923,000 |
| Other Operating Expenses | $-13,890,000 | $-13,620,000 | $-14,155,000 | $-10,554,000 |
| Selling And Marketing Expense | - | $12,779,000 | $14,180,000 | $11,270,000 |
| General And Administrative Expense | - | $72,711,000 | $60,999,000 | $55,485,000 |
| Interest Expense | - | - | - | $4,045,000 |
| Interest Expense Non Operating | - | - | - | $4,045,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-146,412,000 | $-162,857,000 | $-146,398,000 | $158,519,000 |
| Net Interest Income | $28,329,000 | $38,473,000 | $42,247,000 | $16,079,000 |
| Interest Income | $28,329,000 | $38,473,000 | $42,247,000 | $16,079,000 |
| Normalized Income | $-146,412,000 | $-162,857,000 | $-146,398,000 | $158,519,000 |
| Net Income From Continuing And Discontinued Operation | $-146,412,000 | $-162,857,000 | $-146,398,000 | $158,519,000 |
| Total Operating Income As Reported | $-217,103,000 | $-314,766,000 | $-237,207,000 | $216,511,000 |
| Net Income Common Stockholders | $-146,412,000 | $-162,857,000 | $-146,398,000 | $158,519,000 |
| Net Income | $-146,412,000 | $-162,857,000 | $-146,398,000 | $158,519,000 |
| Net Income Including Noncontrolling Interests | $-146,412,000 | $-162,857,000 | $-146,398,000 | $158,519,000 |
| Net Income Continuous Operations | $-146,412,000 | $-162,857,000 | $-146,398,000 | $158,519,000 |
| Pretax Income | $-177,595,000 | $-200,395,000 | $-174,029,000 | $239,099,000 |
| Interest Income Non Operating | $28,329,000 | $38,473,000 | $42,247,000 | $16,079,000 |
| Operating Income | $-203,213,000 | $-301,146,000 | $-223,052,000 | $227,065,000 |
| Depreciation Amortization Depletion Income Statement | $22,171,000 | $90,850,000 | $24,395,000 | $27,843,000 |
| Depreciation And Amortization In Income Statement | $22,171,000 | $90,850,000 | $24,395,000 | $27,843,000 |
| Gross Profit | - | $28,833,000 | $38,025,000 | $418,988,000 |
| Depreciation Income Statement | - | - | - | $27,843,000 |
| Per Share | ||||
| Diluted EPS | $-0.49 | $-0.55 | $-0.51 | $0.50 |
| Basic EPS | $-0.49 | $-0.55 | $-0.51 | $0.56 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-174,392,000 | $-204,148,000 | $-192,158,000 | $260,167,000 |
| Reconciled Depreciation | $28,821,000 | $96,998,000 | $30,894,000 | $33,102,000 |
| EBITDA (Bullshit earnings) | $-174,392,000 | $-204,148,000 | $-192,158,000 | $260,167,000 |
| EBIT | $-203,213,000 | $-301,146,000 | $-223,052,000 | $227,065,000 |
| Diluted Average Shares | $298,707,082 | $294,327,532 | $289,166,486 | $314,827,255 |
| Basic Average Shares | $298,707,082 | $294,327,532 | $289,166,486 | $285,056,606 |
| Diluted NI Availto Com Stockholders | $-146,412,000 | $-162,857,000 | $-146,398,000 | $158,519,000 |
| Tax Provision | $-31,183,000 | $-37,538,000 | $-27,631,000 | $80,580,000 |
| Research And Development | $186,829,000 | $167,259,000 | $175,658,000 | $107,879,000 |
| Selling General And Administration | $83,231,000 | $85,490,000 | $75,179,000 | $66,755,000 |
| Other Gand A | - | $72,711,000 | $60,999,000 | $55,485,000 |
| Otherunder Preferred Stock Dividend | - | - | - | $0 |
| Total Unusual Items | - | - | - | - |
| Total Unusual Items Excluding Goodwill | - | - | - | - |
| Gain On Sale Of Security | - | - | - | - |
Fetched: 2026-06-02
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $880,717,000 | $966,165,000 | $984,087,000 | $1,053,969,000 |
| Total Assets | $1,356,950,000 | $1,360,553,000 | $1,488,094,000 | $1,540,907,000 |
| Total Non Current Assets | $628,718,000 | $609,183,000 | $616,109,000 | $515,416,000 |
| Other Non Current Assets | $51,948,000 | $96,538,000 | $94,244,000 | $46,331,000 |
| Goodwill And Other Intangible Assets | $86,187,000 | $89,919,000 | $168,231,000 | $179,308,000 |
| Other Intangible Assets | $38,381,000 | $42,113,000 | $120,425,000 | $131,502,000 |
| Current Assets | $728,232,000 | $751,370,000 | $871,985,000 | $1,025,491,000 |
| Other Current Assets | $9,670,000 | $8,626,000 | $22,018,000 | $9,064,000 |
| Restricted Cash | $25,000,000 | $25,000,000 | $25,000,000 | $25,000,000 |
| Inventory | $6,336,000 | $0 | $1,107,000 | $1,532,000 |
| Receivables | $153,400,000 | $92,130,000 | $64,382,000 | $103,410,000 |
| Taxes Receivable | $55,695,000 | $26,534,000 | $33,792,000 | $64,817,000 |
| Loans Receivable | $39,412,000 | $31,980,000 | $0 | - |
| Accounts Receivable | $58,293,000 | $33,616,000 | $30,590,000 | $38,593,000 |
| Cash Cash Equivalents And Short Term Investments | $533,826,000 | $625,614,000 | $760,585,000 | $886,485,000 |
| Cash And Cash Equivalents | $128,513,000 | $156,325,000 | $133,320,000 | $386,535,000 |
| Cash Equivalents | $29,300,000 | $29,200,000 | - | - |
| Cash Financial | $99,300,000 | $127,100,000 | - | - |
| Prepaid Assets | - | - | - | $9,064,000 |
| Non Current Prepaid Assets | - | - | - | - |
| Non Current Deferred Assets | - | - | - | - |
| Non Current Deferred Taxes Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $143,218,000 | $65,364,000 | $77,380,000 | $82,258,000 |
| Long Term Debt And Capital Lease Obligation | $137,403,000 | $60,743,000 | $71,222,000 | $76,675,000 |
| Current Debt And Capital Lease Obligation | $5,815,000 | $4,621,000 | $6,158,000 | $5,583,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $390,046,000 | $304,469,000 | $335,776,000 | $307,630,000 |
| Total Non Current Liabilities Net Minority Interest | $325,739,000 | $227,857,000 | $216,763,000 | $189,310,000 |
| Other Non Current Liabilities | $4,768,000 | $7,169,000 | $5,906,000 | $3,086,000 |
| Non Current Deferred Liabilities | $183,568,000 | $159,945,000 | $134,722,000 | $93,495,000 |
| Non Current Deferred Taxes Liabilities | $9,115,000 | $10,052,000 | $30,612,000 | $33,178,000 |
| Current Liabilities | $64,307,000 | $76,612,000 | $119,013,000 | $118,320,000 |
| Current Deferred Liabilities | $22,509,000 | $21,179,000 | $26,070,000 | $27,897,000 |
| Payables And Accrued Expenses | $35,983,000 | $50,812,000 | $86,785,000 | $84,840,000 |
| Payables | $25,228,000 | $42,437,000 | $79,078,000 | $78,386,000 |
| Accounts Payable | $25,228,000 | $34,350,000 | $28,603,000 | $14,828,000 |
| Tradeand Other Payables Non Current | - | $0 | $4,913,000 | $16,054,000 |
| Other Payable | - | $8,087,000 | $50,475,000 | $63,558,000 |
| Total Tax Payable | - | - | - | $0 |
| Income Tax Payable | - | - | - | $0 |
| Other Current Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $966,904,000 | $1,056,084,000 | $1,152,318,000 | $1,233,277,000 |
| Total Equity Gross Minority Interest | $966,904,000 | $1,056,084,000 | $1,152,318,000 | $1,233,277,000 |
| Stockholders Equity | $966,904,000 | $1,056,084,000 | $1,152,318,000 | $1,233,277,000 |
| Gains Losses Not Affecting Retained Earnings | $-4,234,000 | $-4,378,000 | $-1,720,000 | $-1,391,000 |
| Other Equity Adjustments | $-4,234,000 | $-4,378,000 | $-1,720,000 | $-1,391,000 |
| Retained Earnings | $-29,482,000 | $116,930,000 | $279,787,000 | $426,185,000 |
| Long Term Equity Investment | $62,580,000 | $82,297,000 | $65,938,000 | $72,522,000 |
| Other | ||||
| Ordinary Shares Number | $300,600,710 | $295,757,002 | $290,824,970 | $286,851,595 |
| Share Issued | $300,600,710 | $295,757,002 | $290,824,970 | $286,851,595 |
| Tangible Book Value | $880,717,000 | $966,165,000 | $984,087,000 | $1,053,969,000 |
| Invested Capital | $966,904,000 | $1,056,084,000 | $1,152,318,000 | $1,233,277,000 |
| Working Capital | $663,925,000 | $674,758,000 | $752,972,000 | $907,171,000 |
| Capital Lease Obligations | $143,218,000 | $65,364,000 | $77,380,000 | $82,258,000 |
| Total Capitalization | $966,904,000 | $1,056,084,000 | $1,152,318,000 | $1,233,277,000 |
| Additional Paid In Capital | $198,279,000 | $166,361,000 | $121,052,000 | $74,118,000 |
| Capital Stock | $802,341,000 | $777,171,000 | $753,199,000 | $734,365,000 |
| Common Stock | $802,341,000 | $777,171,000 | $753,199,000 | $734,365,000 |
| Non Current Deferred Revenue | $174,453,000 | $149,893,000 | $104,110,000 | $60,317,000 |
| Long Term Capital Lease Obligation | $137,403,000 | $60,743,000 | $71,222,000 | $76,675,000 |
| Current Deferred Revenue | $22,509,000 | $21,179,000 | $26,070,000 | $27,897,000 |
| Current Capital Lease Obligation | $5,815,000 | $4,621,000 | $6,158,000 | $5,583,000 |
| Current Accrued Expenses | $10,755,000 | $8,375,000 | $7,707,000 | $6,454,000 |
| Investments And Advances | $62,580,000 | $82,297,000 | $65,938,000 | $72,522,000 |
| Goodwill | $47,806,000 | $47,806,000 | $47,806,000 | $47,806,000 |
| Net PPE | $428,003,000 | $340,429,000 | $287,696,000 | $217,255,000 |
| Accumulated Depreciation | $-57,614,000 | $-39,718,000 | $-30,608,000 | $-18,475,000 |
| Gross PPE | $485,617,000 | $380,147,000 | $318,304,000 | $235,730,000 |
| Other Properties | $239,052,000 | $150,937,000 | $147,008,000 | $122,094,000 |
| Buildings And Improvements | $193,160,000 | $175,805,000 | $43,947,000 | $11,361,000 |
| Land And Improvements | $53,405,000 | $53,405,000 | $53,405,000 | $53,405,000 |
| Properties | $0 | $0 | $0 | $0 |
| Raw Materials | $6,336,000 | $0 | $1,107,000 | $1,532,000 |
| Other Short Term Investments | $405,313,000 | $469,289,000 | $627,265,000 | $499,950,000 |
| Leases | - | $122,892,000 | $73,944,000 | $40,567,000 |
| Machinery Furniture Equipment | - | - | $3,517,000 | $8,303,000 |
| Other Investments | - | - | - | - |
Fetched: 2026-06-02
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-174,067,000 | $-186,952,000 | $-120,824,000 | $204,700,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-131,295,000 | $-108,556,000 | $-43,877,000 | $277,360,000 |
| Cash Flow From Continuing Operating Activities | $-131,295,000 | $-108,556,000 | $-43,877,000 | $277,360,000 |
| Investing Activities | ||||
| Capital Expenditure | $-42,772,000 | $-78,396,000 | $-76,947,000 | $-72,660,000 |
| Investing Cash Flow | $87,750,000 | $121,409,000 | $-221,108,000 | $-352,625,000 |
| Cash Flow From Continuing Investing Activities | $87,750,000 | $121,409,000 | $-221,108,000 | $-352,625,000 |
| Net Other Investing Changes | $54,611,000 | $35,708,000 | $25,311,000 | $16,434,000 |
| Financing Activities | ||||
| Financing Cash Flow | $14,082,000 | $12,769,000 | $10,356,000 | $-1,628,000 |
| Cash Flow From Continuing Financing Activities | $14,082,000 | $12,769,000 | $10,356,000 | $-1,628,000 |
| Net Other Financing Charges | $14,082,000 | $12,769,000 | $10,356,000 | $-1,628,000 |
| Dividends Received Cfi | $30,113,000 | $0 | $0 | - |
| Issuance Of Capital Stock | - | - | - | $0 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Net Common Stock Issuance | - | - | - | $0 |
| Common Stock Issuance | - | - | - | $0 |
| Other | ||||
| End Cash Position | $155,249,000 | $183,615,000 | $160,610,000 | $414,650,000 |
| Beginning Cash Position | $183,615,000 | $160,610,000 | $414,650,000 | $501,142,000 |
| Effect Of Exchange Rate Changes | $1,097,000 | $-2,617,000 | $589,000 | $-9,599,000 |
| Changes In Cash | $-29,463,000 | $25,622,000 | $-254,629,000 | $-76,893,000 |
| Net Investment Purchase And Sale | $52,935,000 | $183,723,000 | $-155,782,000 | $-270,720,000 |
| Sale Of Investment | $506,072,000 | $948,809,000 | $910,937,000 | $510,631,000 |
| Purchase Of Investment | $-453,137,000 | $-765,086,000 | $-1,066,719,000 | $-781,351,000 |
| Net Business Purchase And Sale | $-7,137,000 | $-19,626,000 | $-13,690,000 | $-25,679,000 |
| Purchase Of Business | $-7,137,000 | $-19,626,000 | $-13,690,000 | $-25,679,000 |
| Net PPE Purchase And Sale | $-42,772,000 | $-78,396,000 | $-76,947,000 | $-70,660,000 |
| Purchase Of PPE | $-42,772,000 | $-78,396,000 | $-76,947,000 | $-70,660,000 |
| Change In Working Capital | $-70,694,000 | $-25,843,000 | $13,225,000 | $29,825,000 |
| Change In Other Working Capital | $-35,676,000 | $32,687,000 | $56,009,000 | $-73,162,000 |
| Change In Other Current Assets | $17,148,000 | $5,954,000 | $18,253,000 | $-1,375,000 |
| Change In Payables And Accrued Expense | $3,457,000 | $10,635,000 | $-15,104,000 | $-2,094,000 |
| Change In Receivables | $-55,623,000 | $-75,119,000 | $-45,933,000 | $106,456,000 |
| Changes In Account Receivables | $-55,623,000 | $-75,119,000 | $-45,933,000 | $-22,715,000 |
| Other Non Cash Items | $1,198,000 | $-84,435,000 | $-5,781,000 | $6,433,000 |
| Stock Based Compensation | $55,792,000 | $67,581,000 | $64,183,000 | $49,481,000 |
| Depreciation Amortization Depletion | $28,821,000 | $96,998,000 | $30,894,000 | $33,102,000 |
| Depreciation And Amortization | $28,821,000 | $96,998,000 | $30,894,000 | $33,102,000 |
| Amortization Cash Flow | $3,732,000 | $78,312,000 | $11,637,000 | $18,890,000 |
| Amortization Of Intangibles | $3,732,000 | $78,312,000 | $11,637,000 | $18,890,000 |
| Depreciation | $25,089,000 | $18,686,000 | $19,257,000 | $14,212,000 |
| Net Income From Continuing Operations | $-146,412,000 | $-162,857,000 | $-146,398,000 | $158,519,000 |
| Net Intangibles Purchase And Sale | - | $0 | $-560,000 | $-2,000,000 |
| Purchase Of Intangibles | - | $0 | $-560,000 | $-2,000,000 |
| Issuance Of Debt | - | - | $11,590,000 | $2,755,000 |
| Net Issuance Payments Of Debt | - | - | $11,590,000 | $2,432,000 |
| Net Long Term Debt Issuance | - | - | $11,590,000 | $2,432,000 |
| Long Term Debt Issuance | - | - | $11,590,000 | $2,755,000 |
| Change In Payable | - | - | $-15,104,000 | $-87,543,000 |
| Change In Account Payable | - | - | $-15,104,000 | $1,066,000 |
| Deferred Tax | - | - | $1,960,000 | $-2,114,000 |
| Deferred Income Tax | - | - | $1,960,000 | $-2,114,000 |
| Repayment Of Debt | - | - | - | $-323,000 |
| Long Term Debt Payments | - | - | - | $-323,000 |
| Change In Other Current Liabilities | - | - | - | $-3,064,000 |
| Change In Accrued Expense | - | - | - | $-3,160,000 |
| Change In Tax Payable | - | - | - | $-88,609,000 |
| Change In Income Tax Payable | - | - | - | $-88,609,000 |
| Proceeds From Stock Option Exercised | - | - | - | - |
| Net Short Term Debt Issuance | - | - | - | - |
Fetched: 2026-06-02